A small clinical trial suggests that a monoclonal antibody treatment from Eli Lilly may slow the progression of Alzheimer's disease, the New York Times reports.
A small clinical trial suggests that a monoclonal antibody treatment from Eli Lilly may slow the progression of Alzheimer's disease, the New York Times reports.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.